Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

Fraile-Ribot, Pablo Arturo; Zamorano, Laura; Orellana, Rocío; del Barrio-Tofiño, Ester; Sánchez-Diener, Irina; Cortés-Lara, Sara; López-Causapé, Carla; Cabot, Gabriel; Bou, Germán; Martínez-Martínez, Luis; Oliver, Antonio

Use this link to cite:

https://hdl.handle.net/2183/46306

Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

Files

zamorano_activity_2020.pdf (450.98 KB)

Identifiers

URI: https://hdl.handle.net/2183/46306

DOI: 10.1128/aac.02165-19

Publication date

2020-01-27

Authors

Fraile-Ribot, Pablo Arturo

Zamorano, Laura

Orellana, Rocío

del Barrio-Tofiño, Ester

Sánchez-Diener, Irina

Cortés-Lara, Sara

López-Causapé, Carla

Cabot, Gabriel

Bou, Germán

Martínez-Martínez, Luis

Bibliographic citation

Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19.

Abstract

[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.